“Global Rheumatoid Arthritis market set to grow to $47bn by 2024” says new Visiongain report

16 December 2018
Pharma

Visiongain has launched a new pharma report Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others.

Demand for RA drugs is on the rise, particularly in developing countries. The TNF inhibitors, which have dominated the market so successfully, are now coming to the end of their patents, opening the way for new biologics and biosimilars to compete for their share of the market. Following the launch of Xeljanz there are other oral DMARDs in development which could potentially undermine the role of the biologics. Changes in the next few years will be critical in determining the future treatment for RA.

The lead analyst of the report commented "one factor driving growth in this market is the discovery of new molecules that are involved in the disease process, hence, new strategies for treating the disease. Molecules such as TNFα, interleukin 6, interleukin 1, and janus kinase have all enabled the development of new treatments to target these molecules.

There are also several restraints on the RA drugs market which discourage the introduction of new drugs. One of these is the increasing pressure from governments to reduce the size of healthcare budgets and restrict the price of drugs. There are also drives to encourage physicians to prescribe generics and biosimilars rather than branded products, and to increase the percentage of patients who receive such products from year to year."

Leading companies featured in the report include AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi, UCB

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1